Atossa Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 12, 2025, ATOS reported earnings of -0.07 USD per share (EPS) for Q3 25, missing the estimate of -0.06 USD, resulting in a -2.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.74% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.06 USD, with revenue projected to reach -- USD, implying an decrease of -14.29% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
Jan 06, 2026 For Q2 26
Estimate
-$0.10
Actual
$0.00
Surprise
+100.00%
FAQ
What were Atossa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Atossa Therapeutics, Inc. Common Stock reported EPS of -$0.07, missing estimates by -2.94%, and revenue of $0.00, 0% as expectations.
How did the market react to Atossa Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.74%, changed from $0.83 before the earnings release to $0.81 the day after.
When is Atossa Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 23, 2026.
What are the forecasts for Atossa Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
analysts, Atossa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of -- for Q4 2025.